APA (7th ed.) Citation

Sung, J., Cheong, J., Shin, K., & Kim, E. T. (2024). A subtype of cancer‐associated fibroblast expressing syndecan‐2 (SDC2) predicts survival and immune checkpoint inhibitor response in gastric cancer. Clinical & Translational Medicine, 14(12), 1. https://doi.org/10.1002/ctm2.70079

Chicago Style (17th ed.) Citation

Sung, Ji‐Yong, Jae‐Ho Cheong, Kihye Shin, and Eui Tae Kim. "A Subtype of Cancer‐associated Fibroblast Expressing Syndecan‐2 (SDC2) Predicts Survival and Immune Checkpoint Inhibitor Response in Gastric Cancer." Clinical & Translational Medicine 14, no. 12 (2024): 1. https://doi.org/10.1002/ctm2.70079.

MLA (9th ed.) Citation

Sung, Ji‐Yong, et al. "A Subtype of Cancer‐associated Fibroblast Expressing Syndecan‐2 (SDC2) Predicts Survival and Immune Checkpoint Inhibitor Response in Gastric Cancer." Clinical & Translational Medicine, vol. 14, no. 12, 2024, p. 1, https://doi.org/10.1002/ctm2.70079.